Publications by authors named "S Mısırcı"
The primary aim of our study was to evaluate the demographic, clinical, and laboratory characteristics of sarcoidosis patients with musculoskeletal symptoms; investigate the relationship between arthritis development and various laboratory parameters (such as vitamin D, liver enzymes, and ACE levels); and compare the sarcoidosis-associated arthritis cases with those without. We also explored the factors influencing arthritis development and the role of biopsy in diagnosing sarcoidosis within rheumatology practice. This retrospective study analyzed 147 sarcoidosis patients from 2000 to 2024, categorized by the presence ( = 45) or absence ( = 102) of arthritis.
View Article and Find Full Text PDFBackground/objectives: The objective of this study was to evaluate the diagnostic accuracy of the lactate dehydrogenase-to-albumin ratio (LAR) in adult-onset Still's disease (AOSD) and compare it with other inflammatory indices, using patients with fever of unknown origin (FUO) as a control group due to their overlapping clinical features with AOSD. The study also compared LAR's diagnostic performance with other inflammatory indices like the serum immune-inflammatory index (SII), ferritin/erythrocyte sedimentation rate (FER), CRP/albumin ratio (CAR), platelet/lymphocyte ratio (PLR), and neutrophil/lymphocyte ratio (NLR), as well as its combinations with FER, PLR, and ferritin (LAR + FER, LAR + PLR, LAR + ferritin).
Methods: A retrospective evaluation was conducted on 70 patients with fever of unknown cause and 78 patients with AOSD, admitted between January 2000 and December 2023 in a tertiary care hospital.
Tofacitinib is a targeted JAK inhibitor used to treat rheumatoid arthritis. Despite some recent safety concerns, it is considered effective and safe with appropriate patient selection. Between May 2015 and May 2024, data were retrospectively analyzed from 112 patients with a diagnosis of RA in a tertiary care hospital who had received tofacitinib for at least 1 month, with or without prior biologic DMARDs.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to validate the 2023 ACR/EULAR classification criteria for antiphospholipid syndrome (APS) in a group of 193 patients, 83 of whom had APS.
- The new criteria showed a sensitivity of 73% and specificity of 94%, while the revised Sapporo criteria had a sensitivity of 66% and specificity of 98%.
- Despite the new criteria offering a broader classification scope, they had lower sensitivity in this cohort, especially improving to 100% specificity when excluding certain clinical findings.
Article Synopsis
- The study evaluates the effectiveness and safety of baricitinib, an oral DMARD, in treating patients with difficult-to-treat rheumatoid arthritis (D2T RA) compared to those without it.
- A total of 78 patients were analyzed, revealing that both D2T RA and non-D2T RA groups showed significant improvement in disease activity and scores after 12 months of treatment, though infection was the most common side effect.
- The findings suggest that baricitinib is a viable treatment option for D2T RA, with safety and efficacy profiles that are comparable to patients without this classification.